Transthyretin Amyloid Cardiomyopathy (ATTR-CM) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Therapy and TPP Insights

Thelansis’s “Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Overview

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of systemic amyloidosis characterized by misfolded transthyretin (TTR) protein deposition in the myocardium. Another notable cause of cardiac amyloidosis is the accumulation of immunoglobulin light-chain (AL) aggregates. Although several amyloidogenic proteins may be deposited in various organs and tissues, myocardial involvement is rare. Symptoms of ATTR-CM can vary, and the condition is frequently misdiagnosed, with early stages resembling symptoms of other conditions such as hypertensive heart failure or hypertrophic cardiomyopathy. Some patients may be asymptomatic, while others may progress to end-stage heart failure. The disease is classified based on the sequence of the TTR gene, distinguishing between wtATTR-CM (no mutation) and hATTR-CM (presence of a mutation). In 2019, the FDA approved tafamidis and tafamidis meglumine for treating ATTR-CM. Both agents selectively bind to the transthyretin tetramer, preventing the destabilization of the transthyretin transport protein and the subsequent amyloid formation that leads to ATTR-CM.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)